4-Demethylpenclomedine, an antitumor-active, potentially nonneurotoxic metabolite of penclomedine

Cancer Research

Volumn 57, Issue 5, 1997, Pages 815-817

  Waud, William R ^a   Tiwari, Anita ^a   Schmid, Steven M ^a   Shih, Tsu Wen ^a   Strong, John M ^b   Hartman, Neil R ^b   O'Reilly, Seamus ^c   Struck, Robert F ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEMETHYLPENCLOMEDINE; ALPHA,ALPHA DIDECHLOROPENCLOMEDINE; DRUG METABOLITE; PENCLOMEDINE; PENCLOMEDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BREAST NEOPLASMS; HUMANS; LEUKEMIA P388; MALE; MICE; MICE, NUDE; MICROSOMES, LIVER; NEOPLASM TRANSPLANTATION; PICOLINES; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031029575     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Hartman, N. R., O'Reilly, S., Rowinsky, E. K., Collins, J. M., and Strong, J. M. Murine and human in vivo penclomedine metabolism, Clin. Cancer Res., 2: 953-962, 1996.
2. 14C-penclomedine in rats. Clin. Cancer Res., 2: 541-548, 1996.
3. Berlin, J., Stewart, J., Tutsch, K., Stover, B. Arzoomanian, R., Alberti, D., Feierabend, C., and Wilding, G. Phase I and pharmacokinetic trial of penclomedine, Proc. Am. Assoc. Cancer Res., 36: 238, 1995.
4. O'Reilly, S., Grochow, L., Donehower, R. C., Bowling, K., Chen, T. L., Sartorius, S., Roskes, E., Ludeman, S., Hartman, N., Strong, J., Struck, R., and Rowinsky, E. K. Phase I and pharmacologic studies of penclomedine, a novel alkylating agent with prominent preclinical activity in breast cancer. Proc. Am. Soc. Clin. Oncol., 14: 471, 1995.
5. Plowman, J., Harrison, S. D., Jr., Dykes, D. J., Paull, K. D., Narayanan, V. L., Tobol, H. K., Martin, J., and Griswold, D. P., Jr. Preclinical antitumor activity of an α-picoline derivative, penclomedine (NSC 338720). on human and murine tumors. Cancer Res., 49: 1909-1915, 1989.
6. Harrison, S. D., Jr., Plowman, J., Dykes, D. J., Waud, W. R., and Griswold, D. P., Jr. Preclinical antitumor activity of penclomedine in mice: cross-resistance, schedule-dependence, and oral activity against tumor xenografts in brain. Cancer Res., 51: 1979-1983, 1991.
7. O'Reilly, S., O'Hearn, E., Rowinsky, E. K., Struck, R. F., and Molliver, M. E. Neuroanatomic studies of the cerebellar effects of penclomedine. Proc. Am. Assoc. Cancer Res., 37: 374-375, 1996.
8. Reid, J. M., Mathiesen, D. A., Benson, L. M., Kuffel, M. J., and Ames, M. M. Murine pharmacokinetics and metabolism of penclomedine [3.5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 3387201. Cancer Res., 52: 2830-2834, 1992.
9. Struck, R. F., Schmid, S. M., and Waud, W. R. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide. Cancer Chemother. Pharmacol., 34: 191-196, 1994.